Abstract
Investigating the role of intrinsic cell heterogeneity emerging from variations in cell-cycle parameters and apoptosis is a crucial step toward better informing drug administration. Antimitotic agents, widely used in chemotherapy, target exclusively proliferative cells and commonly induce a prolonged mitotic arrest followed by cell death via apoptosis. In this paper, we developed a physiologically motivated mathematical framework for describing cancer cell growth dynamics that incorporates the intrinsic heterogeneity in the time individual cells spend in the cell-cycle and apoptosis process. More precisely, our model comprises two age-structured partial differential equations for the proliferative and apoptotic cell compartments and one ordinary differential equation for the quiescent compartment. To reflect the intrinsic cell heterogeneity that governs the growth dynamics, proliferative and apoptotic cells are structured in “age,” i.e., the amount of time remaining to be spent in each respective compartment. In our model, we considered an antimitotic drug whose effect on the cellular dynamics is to induce mitotic arrest, extending the average cell-cycle length. The prolonged mitotic arrest induced by the drug can trigger apoptosis if the time a cell will spend in the cell cycle is greater than the mitotic arrest threshold. We studied the drug’s effect on the long-term cancer cell growth dynamics using different durations of prolonged mitotic arrest induced by the drug. Our numerical simulations suggest that at confluence and in the absence of the drug, quiescence is the long-term asymptotic behavior emerging from the cancer cell growth dynamics. This pattern is maintained in the presence of small increases in the average cell-cycle length. However, intermediate increases in cell-cycle length markedly decrease the total number of cells and can drive the cancer population to extinction. Intriguingly, a large “switch-on/switch-off” increase in the average cell-cycle length maintains an active cell population in the long term, with oscillating numbers of proliferative cells and a relatively constant quiescent cell number.
Highlights
Intratumoral cancer heterogeneity represents a major obstacle to improving the overall response and survival of cancer patients [1,2,3,4]
This work is aimed at understanding cancer cell growth dynamics in the context of cancer heterogeneity emerging from variations in cell-cycle and apoptosis parameters
We considered an antimitotic drug whose effect on at any given time and to temporally trace the distribution of the the cellular dynamics is to induce mitotic arrest, extending the times remaining to be spent in the proliferative phase during the average cell-cycle length
Summary
Intratumoral cancer heterogeneity represents a major obstacle to improving the overall response and survival of cancer patients [1,2,3,4]. Antimitotic cancer drugs represent a highly diverse and successful class of antimitotic agents, reported to have a broad spectrum of potent anti-tumor activity in various hematological and solid malignancies [7, 11,12,13,14,15,16,17] Examples of such drugs include microtubule-targeting agents, e.g., taxanes and vinca alkaloids, and newer agents that disrupt mitosis without affecting microtubule dynamics, e.g., kinesin spindle protein inhibitors and inhibitors of mitotic kinases [18,19,20,21,22,23,24,25,26,27,28]. They found that cellular responses to identical drugs are heterogeneous, e.g., within each distinct cell line, cells exhibit different responses following prolonged mitotic arrest, such as undergoing apoptosis after exiting mitosis, dying after completing several mitoses, or dying in interphase
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.